Evidence map›Paper›PMID 33563835›Full record

ArticlemBio2021

Is It Time To Kill the Survival Curve? A Case for Disease Progression Factors in Microbial Pathogenesis and Host Defense Research.

Robert A Cramer, Caitlin H Kowalski

Abstract read
In one paragraph

Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Recent developments inMicrobiology and molecular biology reviews : MMBR · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Robert A CramerDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA Robert.a.cramer.jr@dartmouth.edu.ORCID 0000-0001-5503-5006
Caitlin H KowalskiDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.

Funding

Evolution of Aspergillus fumigatus virulenceR01AI130128 · NIAID · DARTMOUTH COLLEGE · PI Robert Andrew Cramer · 2017 to 2026
$4.5M
Environmental Oxygen Transitions and Aspergillosis Disease ProgressionR01AI146121 · NIAID · DARTMOUTH COLLEGE · PI CRAMER, ROBERT ANDREW · 2019 to 2023
$2.6M
Fungal Collagen-Like Proteins Mediate Oxygen Acquisition and VirulenceF31AI138354 · NIAID · DARTMOUTH COLLEGE · PI KOWALSKI, CAITLIN H. · 2018 to 2019
$90k
NIAID NIH HHS F31 AI138354NIAID NIH HHS R01 AI130128NIAID NIH HHS R01 AI146121
6 · The paper itself

Abstract

The molecular mechanisms of microbial virulence and host defense are most often studied using animal models and Koch's molecular postulates. A common rationale for these types of experiments is to identify therapeutic targets based on the assumption that microbial or host factors that confer extreme animal model survival phenotypes represent critical virulence and host defense factors. Yet null mutant strains of microbial (or host) factors often yield extreme survival curve phenotypes because they fail to establish an infection. The lack of infection and disease establishment prevents true assessment of the given factor's role(s) in disease progression. Here, we posit that the emphasis on extreme survival curve phenotypes in fungal infectious disease models is leading to missed opportunities to identify new fungal and host factors critical for disease progression. We simply do not yet have a sufficient understanding of fungal virulence and host defense mechanisms throughout the temporal course of an infection. We propose that there is a need to develop new approaches and to revisit tried and true methods to define infection site biology beyond the analysis of survival curve phenotypes. To stimulate these new approaches, we propose the (new) terms "disease initiation factor" and "disease progression factor" to distinguish functional roles at distinct temporal stages of an infection and give us targets to foster new discoveries.

Indexed as

Disease ProgressionHost-Pathogen InteractionsResearchFungiHumansMycosesPhenotypeVirulenceVirulence FactorsVirulence Factorsanimal modelsdrug targetsfungal pathogenesisfungal virulenceinfection site

Identifiers

PMID33563835
PMCPMC7885121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.